InFocus: Life Sciences & Healthcare e-newsletter - July 2012
Welcome to the July issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look at:
Features
- Unlicensed and off-label use of medicines in the UK - A balancing act
- The Bribery Act one year on - The impact for life sciences companies
- Doing business in the UK - Opportunities for healthcare and life sciences providers and suppliers
- Securing border protection for intellectual property rights in China
Case comment
- Compassionate usage provisions in EU law abused in Poland
- Medeva - The UK Court of Appeal has its say
- Preventing an ex-employee setting up in competition - Lessons from a recent case
- Advocate General recommends that the ECJ dismiss AstraZeneca's appeal against Losec antitrust decision
- Cross-border injunctions: Have they a future?
- AG's Opinion in Neurim
- Euro-defences fail in grey market Oracle case
- Tomatoes II - Opposition to tomato patent goes back to EBA
Hot topics
- Medical device regulation - Update on the EU reform initiatives
- Biosimilars - CHMP adopts biosimilar monoclonal antibody and immunogenicity assessment guidelines
- Seed investment documents: Now available on the TW Tech Focus microsite
- The European patent package - Update
- Pharmacovigilance - New pharmacovigilance legislation comes into effect across the EU
- Pharmacovigilance and social media - MHRA clarifies level of monitoring of the internet required under new legislation
- Guide to insolvency and enforcement procedures in the UK
Lawyers Malcolm Bates, Dr. Jingjing Cao, Simon Cohen, Richard Craig, Agnieszka Deeg-Tyburska, Rachel Farr, Dr. Anja Lunze, Claire Martin-Royle, Nick Moser, Louisa Penny, Timothy Pinto, Matthew Royle, Talitha Shkopiak, Neil Smyth, Stephen Tainsh, Edward Vickers, Robert Vidal, Tim Worden
